Incannex Healthcare Limited (ASX:IHL)


right-arrow Created with Sketch. 0.025 (5.81%)
MCAP $549.8M
Last trade 16.10pm 28/01/2022 20mins delayed

Latest Announcements

28/01/2022IHLIncannex Healthcare Limited
20/01/2022IHLIncannex Healthcare Limited
20/01/2022 Price SensitivePSIHLIncannex Healthcare Limited
18/01/2022IHLIncannex Healthcare Limited
17/01/2022IHLIncannex Healthcare Limited
20/12/2021 Price SensitivePSIHLIncannex Healthcare Limited
20/12/2021IHLIncannex Healthcare Limited
17/12/2021 Price SensitivePSIHLIncannex Healthcare Limited

Company Overview

Incannex Healthcare Limited is an Australia-based company. It is a clinical stage pharmaceutical development company. The Company is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).

IHL in the news

Participants in Incannex Healthcare’s (IHL) phase two, proof-of-concept clinical study testing a…
Medicinal cannabis business Incannex Healthcare (IHL) is finalising its US Public Offering…
Incannex Healthcare (IHL) spikes on the ASX today after landing important regulatory…
Incannex Healthcare (IHL) has engaged Procaps S.A. to manufacture its soft-gel capsules…

Search Previous Announcements